UroGen Pharma Ltd. — Director's Dealing 2025

Jul 30, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2025-07-28

Reporting Person: Barrett Elizabeth A. (Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-07-28	Performance Stock Units	$	A	87615	Acquired		Ordinary Shares (87615)	Direct

Footnotes

F1: Each performance stock unit represents a contingent right to receive one ordinary share of the Issuer.

F2: Represents performance stock units ("PSUs") granted to the reporting person on January 31, 2024 that were earned upon the achievement of a corporate milestone event. These PSUs remain subject to continued service through December 31, 2025, at which time they will vest and settle in ordinary shares.